{
    "id": 12080,
    "cites": 7,
    "cited_by": 15,
    "reference": [
        "INSURANCE AND INCENTIVES FOR MEDICAL INNOVATION 29 Gaynor, Martin, Deborah Haas-Wilson, and William B. Vogt, Are Invisible Hands Good Hands? Moral Hazard, Competition, and the Second-Best in Health Care Markets, Journal of Political Economy, 2000, 108, 992-1005.",
        "Goldman, D.P., G.E Joyce, and P. Karaca-Madic, Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy, American Journal of Managed Care, 2006, 12, 17-28.",
        "Lakdawalla, Darius and Neeraj Sood, Insurance and Innovation in Health Care Markets, September 2005. NBER Working Paper 11602.",
        "Pauly, Mark V., The Economics of Moral Hazard: Comment, American Economic Review, June 1968, 58, 53 1-537.",
        "Philipson, Tomas J. and Anupam B. Jena, Who Benefits from New Medical Technologies ? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs, December 2005. NBER Working Paper 11810.",
        "Rosen, A.B., M.B. Hamel, M.C. Weinstein, D.M. Cutler, A.M. Fendrick, and S. Vijan, Cost effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes, Annals of Internal Medicine, 2005, 143, 89-99.",
        "Saez, Emmanuel, Using Elasticities to Derive Optimal Tax Rates, Review of Economic Studies, 2001, 68, 205-229."
    ]
}